Long-acting injectable antipsychotics in first-episode schizophrenia

Hyun Ghang Jeong, Moon Soo Lee

    Research output: Contribution to journalArticlepeer-review

    15 Citations (Scopus)

    Abstract

    Antipsychotic medications are important for the successful management of schizophrenia. Continuous treatment with medication is superior in relapse prevention and non-adherence to antipsychotic medication is associated with a poor clinical outcome. Long-acting injectable antipsychotics (LAIs) that can guarantee adherence to a treatment regimen could be a useful treatment option. With the introduction of second-generation atypical antipsychotics-long acting injection (SGA-LAI), the risks for extrapyramidal adverse events are decreased. The indications for SGA-LAI have been extended from chronic, stabilized patients to acute psychotic patients. Some studies investigated the use of LAI in first-episode schizophrenia patients and raised the possibility of prescribing LAI as a treatment option. However, there is still limited research using LAI in first-episode schizophrenia. More well-designed, randomized, controlled clinical trials using SGA-LAIs in first episode schizophrenia are needed. Additionally, studies on side effects of SGA-LAI in long-term use are required prior to recommending LAI for patients with first episode schizophrenia.

    Original languageEnglish
    Pages (from-to)1-6
    Number of pages6
    JournalClinical Psychopharmacology and Neuroscience
    Volume11
    Issue number1
    DOIs
    Publication statusPublished - 2013 Apr

    Keywords

    • Antipsychotic agents
    • Delayed-action preparations
    • Injections
    • Schizophrenia

    ASJC Scopus subject areas

    • Psychiatry and Mental health
    • Behavioral Neuroscience
    • Pharmacology (medical)

    Fingerprint

    Dive into the research topics of 'Long-acting injectable antipsychotics in first-episode schizophrenia'. Together they form a unique fingerprint.

    Cite this